Liu, X., Shaw, R., Stuart, A., Greenland, M., Aley, P., Andrews, N., Cameron, C., Charlton, S., Clutterbuck, E., Collins, A., Dinesh, T., England, A., Faust, S., Ferreira, D., Finn, A., Green, C., Hallis, B., Heath, P., Hill, H., Lambe, T., Lazarus, R., Libri, V., Long, F., Mujadidi, Y., Plested, E., Provstgaard-Morys, S., Ramasamy, M., Ramsay, M., Read, R., Robinson, H., Singh, N., Turner, D., Turner, P., Walker, L., White, R., Nguyen-Van-Tam, J., Snape, M. & Com-COV Study Group 2021, 'Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial', The Lancet, 398(10303), pp. 856-869. https://doi.org/10.1016/S0140-6736(21)01694-9